Inmagene Biopharmaceuticals picks up $21m Series B
Inmagene Biopharmaceuticals, a Chinese drug developer, has secured $21 million in Series B financing.
Inmagene Biopharmaceuticals, a Chinese drug developer, has secured $21 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination